THER-09. ONCOLYTIC ADENOVIRUS, DNX-2401, FOR NAIVE DIFFUSE INTRINSIC PONTINE GLIOMAS: A PHASE I CLINICAL TRIAL

The objective of this trial is to determine the safety, tolerability, and toxicity of DNX-2401 in newly diagnosed DIPG patients (NCT03178032) followed by radiotherapy. Secondary endpoints are overall survival at 12 months, percentage of responses and induced immune response against tumor. Tumor biop...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Iñigo-Marco, Ignacio, Gonzalez-Huarriz, Marisol, García-Moure, Marc, Tamayo, Ibon, Hervas, Sandra, Hernandez, Ruben, Buñales, Maria, DeAndrea, Carlos, Villalba, Maria, Jones, Chris, MacKay, Alan, Hulleman, Esther, Van der Lugt, Jasper, Aldave, Guillermo, Lopez-Ibor, Blanca, Patiño-Garcia, Ana, Diez-Valle, Ricardo, Fueyo, Juan, Gomez-Manzano, Candelaria, de Larraya, Jaime Gallego Perez, Tejada, Sonia, Alonso, Marta M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Viral/Gene Therapy and other Novel Therapies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715674/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.859
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars